Results 151 to 160 of about 45,696 (262)

Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae

, 2017
The efficacy of ceftazidime-avibactam - a cephalosporin-β-lactamase inhibitor combination with in vitro activity against Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) - as compared to colistin remains ...
Lok, Judith J., Earley, Michelle, Salata, Robert A., Cober, Eric, Kaye, Keith S., van Duin, David, Bonomo, Robert A., Evans, Scott, Richter, Sandra S., Watkins, Richard R., Perez, Federico, Doi, Yohei, Paterson, David L., Kalayjian, Robert C., Fowler, Vance G.   +14 more
core   +1 more source

Correction to “Persistent Burkholderia cepacia Bacteremia in Reconstructive Surgery: Resistance to Ceftazidime/Avibactam and Co‐Trimoxazole With Risk of Infective Endocarditis—A Case Report”

Clinical Case Reports, Volume 14, Issue 2, February 2026.
wiley   +1 more source

Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study

Infection and Drug Resistance
Introduction Recent studies suggested the potential benefits of extended infusion times to optimize the treatment efficacy of ceftazidime/avibactam, which indicated that the current pharmacokinetic/pharmacodynamic (PK/PD) target may not be sufficient ...
Yun Han, Jianping Zhu, Jieqiong Liu, Ying Zheng, Gang Liang, Yi Yang, Lingyan Yu, Zhenwei Yu, Gang Han   +8 more
semanticscholar   +1 more source

Effectiveness of Ceftazidime/Avibactam treatment for infections caused by Klebsiella pneumoniae Carbapenemase (KPC), a 30-day mortality perspective. Comparison of results with control groups treated with other antibiotics

Journal of Education, Health and Sport
Introduction: Infections caused by Klebsiella pneumoniae carbapenemase (KPC) pose a significant clinical challenge due to increasing antibiotic resistance.
Patrycja Paschke, Igor Miczek, Maria Sambura, Sara Rosołowska-Żak, Julia Pałuchowska, Anna Szymkowicz   +5 more
doaj   +1 more source

Ceftazidime-avibactam susceptibility against Escherichia coli and Klebsiella pneumoniae

Iranian Journal of Microbiology
Background and Objectives: Carbapenem-resistant Enterobacteriaceae (CRE) infections are extremely difficult to treat and have a high fatality rate. The study's primary goal was to determine the rate of ceftazidime-avibactam susceptibility using disc diffusion and E-Test, as well as to evaluate the agreement between the two methods.
Arun Sachu, Alice David
openaire   +3 more sources

KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study

, 2018
KPC-producing Klebsiella pneumoniae (KPC-Kp) gut colonization is a major risk factor for developing systemic infections. Ceftazidime/avibactam could have a role as decolonization therapy in special situations PATIENTS AND METHODS: retrospective ...
Pallotto, Carlo, Sodano, Giuseppe, Righi, Elda, Righi E., Graziano, Elena, Carannante N., Di Caprio G., Bernardo M., Sodano G., Bernardo, Mariano, Tascini C., Sartor, Assunta, Carannante, Novella, Tascini, Carlo, Bassetti, Matteo, Mallardo, Enza, Mallardo E., Sartor A., Di Caprio, Giovanni, Bassetti M., Graziano E., Francisci D., Pallotto C., Francisci, Daniela   +23 more
core   +1 more source

Ceftazidime/avibactam for specified infections [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

Pharmacology Research & Perspectives
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in ...
Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher‐Bournaud, Jean‐Marc Tréluyer, Mehdi Oualha   +5 more
doaj   +1 more source

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study

Introduction: The World Health Organization has declared carbapenem-resistant organisms a research and development priority. Although ceftazidime–avibactam was approved around a decade ago, there is still a lack of prospective data on the treatment of ...
Frieder Pfäfflin, Anja Theloe, Leif Erik Sander, Stephan Achterberg, Rasmus Leistner, Miriam Songa Stegemann, Florian Kurth   +6 more
core   +1 more source

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant <i>Escherichia coli</i>. [PDF]

Antimicrob Agents Chemother
Shropshire WC, Borjan J, Fonseca IY, Pham K, Guerrero M, Liboro K, Young A, Chung JK, Wu C-T, Manzanares A, Bhatti MM, Vuong NN, Handley G, Spallone A, Chemaly RF, Khan A, Shelburne S.   +16 more
europepmc   +1 more source